Loading...
•
Sep 30, 2023
Celldex Q3 2023 Earnings Report
Reported financial results for the third quarter and provided a corporate update.
Key Takeaways
Celldex Therapeutics reported its Q3 2023 financial results, with total revenue of $1.5 million and a net loss of $38.3 million, or ($0.81) per share. The company's cash, cash equivalents, and marketable securities totaled $235.3 million as of September 30, 2023, expected to fund operations through 2025.
Completed enrollment of Phase 2 chronic spontaneous urticaria study ahead of schedule; topline data expected by year-end 2023.
Phase 1b prurigo nodularis data accepted at World Congress on Itch.
Actively planning for the initiation of a Phase 2 study early next year for prurigo nodularis.
Enrollment continues as planned for Phase 2 studies in chronic inducible urticaria and eosinophilic esophagitis with data readouts expected in 2024 and beyond.
Forward Guidance
Celldex believes that the cash, cash equivalents and marketable securities at September 30, 2023 are sufficient to meet estimated working capital requirements and fund planned operations through 2025, which include our ongoing and planned Phase 2 studies in CSU, CIndU, EoE, and PN.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...